NCT06714058 Cardiometabolic Risk of Obese Subjects: Cross-sectional Study
| NCT ID | NCT06714058 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Obesity and Obesity-related Medical Conditions |
| Study Type | OBSERVATIONAL |
| Enrollment | 240 participants |
| Start Date | 2024-11-30 |
| Primary Completion | 2025-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 240 participants in total. It began in 2024-11-30 with a primary completion date of 2025-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
experimental study with analysis on tissues. This study aims to study cardiometabolic risk from a genetic, clinical, instrumental and laboratory point of view in a population of subjects with obesity.
Eligibility Criteria
Inclusion Criteria: * • Age \> 18 years * BMI \> 30 Kg/m2 * In primary prevention for cardiovascular disease * Ability to communicate, make themselves understood and adhere to study-specific procedures * Willingness to participate in the study and obtain informed consent Exclusion Criteria: * Patients already enrolled by the Research Units involved in the enrolment * Glycated hemoglobin level \> 55 mmol/L * Patients suffering from obesity secondary to endocrinological diseases or iatrogenic causes * Patients with heterozygous Familial Hypercholesterolemia (Dutch Lipid Score - DLS\>8) * Patients suffering from hypercholesterolemia secondary to lipid or iatrogenic extra-metabolic pathologies * Patients suffering from systemic inflammatory or oncological diseases * Patients on active treatment with GLP-1 analogues * Pregnancy and breastfeeding * Any medical or surgical condition that makes the patient's adherence to the study protocol complex or inconsistent.
Contact & Investigator
Maria Letizia Petroni, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06714058 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Obesity and Obesity-related Medical Conditions. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06714058 currently recruiting?
Yes, NCT06714058 is actively recruiting participants. Contact the research team at marialetizia.petroni@unibo.it for enrollment information.
Where is the NCT06714058 trial being conducted?
This trial is being conducted at Bologna, Italy, Catanzaro, Italy.
Who is sponsoring the NCT06714058 clinical trial?
NCT06714058 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Maria Letizia Petroni, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 240 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.